Cancer Blog
- Dr. Robert Nagourney -

Biliary tract cancer afflicts 8,000 patients in the US each year. It is separated into intrahepatic and and extrahepatic.

metabolomics are poised to revolutionize breast cancer screening by enhancing diagnostic accuracy and reducing patient discomfort.

Treatments should really be given more selectively, i.e. “give this chemotherapy only to those people who will benefit from it,” She said.

I received a video from an episode of Americas Got Talent, the popular TV program that features up-and-coming performers.

Genomic findings are a first step. They find targets. The question the patient wants to answer is “Can I hit the target?”

Even here in the potentially curable pancreatic cancer patients, there is a great deal of disagreement on the best treatment.

Screening for Pancreatic cancer, even in the highest-risk individuals found not cost effective.

Blood test results offer a “cancer signature” that distinguishes patients with pancreatic cancer from normal individuals.

The NAPOLI-3 trail trial median survival of 11.1 months is exactly the same as the original FOLFIRINOX regimen from 13 years ago.

One of the critical advantages of Functional Profiling over traditional genomic testing is its focus on the actual response of cancer cells.

Cancer patients approach their diagnosis with a sense of terror. One day they are fine and feeling well and the next, a terminal diagnosis.

Rising corporate influence and focus on reimbursement in medicine now discourage doctors from straying from strict treatment guidelines.

Cancer therapy can be really expensive. But here's the kicker, Functional Profiling costs way less than receiving the incorrect treatment.

Patients with advanced malignancies often seek the expertise of physicians at major institutions.

Although she showed some response, her disease persisted and she was being considered for surgery to remove the residual tumor...

Personalized treatment means more cured patients. More people survive cancer when our Functional Profiling system is used before treatment.

However, a new dilemma has arisen; the failure of surgeons to comply with Pancreatic Cancer patient’s wishes to have tissue submitted.

Here in 2023, we suddenly discover that TIL cells are highly active against cancer, but it was Steven Rosenberg who first described it.

There has been talk of improved survival in cancer, most progress has reflected screening, early diagnosis, improved staging, and support.

One noteworthy case was a 78-year-old patient successfully treated without surgery.